A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. - Wikidata - wikimedia - TriplyDB

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

http://www.wikidata.org/entity/Q33401476

about

FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience Adjuvant therapy for pancreas cancer in an era of value based cancer care Perspectives in the treatment of pancreatic adenocarcinoma Management of borderline and locally advanced pancreatic cancer: where do we stand?Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer Advances in chemotherapy for pancreatic cancer Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer.Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.Recent treatment advances and novel therapies in pancreas cancer: a review.Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain.Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives.Neoadjuvant therapy in pancreatic cancer: an emerging strategy Neoadjuvant strategies for pancreatic cancer Role of neoadjuvant therapy in the management of pancreatic cancer: is the era of biomarker-directed therapy here?Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer The role of the FOLFIRINOX regimen for advanced pancreatic cancer.Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer.Improving outcomes in pancreatic cancer: key points in perioperative management CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future.Metastasized pancreatic carcinoma with neoadjuvant FOLFIRINOX therapy and R0 resection.Prolonged Complete Response in a Patient with Metastatic Pancreatic Adenocarcinoma after FOLFIRINOX Chemotherapy and Maintenance with FOLFIRI Pancreatic cancer and FOLFIRINOX: a new era and new questions.Phase II trial of selective internal radiation therapy and systemic chemotherapy for liver-predominant metastases from pancreatic adenocarcinoma.Eastern Canadian Gastrointestinal Cancer Consensus Conference 2014.Update on the Management of Pancreatic Cancer in Older Adults.Neoadjuvant FOLFIRINOX application in borderline resectable pancreatic adenocarcinoma: a retrospective cohort study.Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review Pancreatic Cancer: Progress in Systemic Therapy.Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.Response evaluation following neoadjuvant treatment of pancreatic cancer patients FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma FOLFIRINOX in locally advanced pancreas adenocarcinoma: back to the future?Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma.Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.The controversial role of chemoradiation for patients with locally advanced pancreatic cancer.Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.

P2860

Q24622390-348394F7-F1CE-42F2-99B2-D2D51052DFEE Q26775916-08D03761-AD70-416A-84A7-F9D35601C451 Q26797248-6774C78D-62B4-4C6F-B25C-1BCA3294A719 Q26825414-CE21C2DA-359E-461D-8D88-3DF4AF63A306 Q28072210-5F73EEC3-60E3-4784-B93E-6BC068D961A5 Q28085711-59C8EAEF-C57C-4C2F-BE90-40ADF43E969E Q30414737-B5EEBF93-7A87-48C8-BF75-1D100F241188 Q33418472-207DD312-EF59-478A-B3BF-81C4DCEAE753 Q33609699-15BA1544-AF0C-429C-B9B3-9A734026CB6B Q33625168-8181E050-8669-4897-A43C-DE007CBCDCEF Q33665450-71542B52-E899-401B-AA2F-F5ED9F5F79FB Q33750803-4AA4E9ED-F6F2-4211-8D37-DAB5820B19EA Q33751263-B5749790-921B-4B69-8835-8657048DDFA8 Q33914671-E2DFB78A-4EDE-4E21-BF6F-7EE7BE53D31C Q33948343-99563367-0092-41C7-857B-34001DA688E6 Q33982773-33E340EB-3373-466E-A52D-CC09D5BB5C76 Q33997265-49D2C1D8-5388-4CDB-8756-D44D55990E29 Q34323833-BB2F97E8-626C-4692-AF61-8F061E9A8F5D Q34357427-A73D6CBF-7E25-4B62-A2A6-440055A716E4 Q34366880-B0EC1FC0-D5E9-4526-8820-07A2D5AF9D0A Q34646563-01B3756E-7710-4794-B5D9-517BFC07DDE2 Q34896040-E0E0F205-CA65-4A7C-B4A1-70F780575872 Q35604577-40994A7D-E19C-4CCD-A147-878E07268808 Q35651591-782C6B69-4A8D-4B10-92E7-5A7DBD962B28 Q35680690-8D8DCD51-1B63-4859-AD35-46F19C5B9601 Q35755386-9D723C4C-7279-4DDD-8F90-43DC40938773 Q35822196-01871A44-D624-4F12-A8D4-F25C520B71DC Q35934322-1C6456A6-4626-4D42-B6DC-89C2ACEA786C Q36095529-CFFA1828-3870-4F37-91F6-6E48C4491ECD Q36152545-66CEBD1F-7509-406C-93B6-DB6E26C62D5E Q36159880-DE1AEEEF-EDC9-4F4C-8633-9FC0F55188AE Q36344551-A25C80E0-01BE-4CE5-B631-E102A828CA74 Q36558415-CBAC3BC1-A27C-413C-9934-0AA986B0629D Q36693226-18AF1547-9410-45D3-A42D-95A348F696A7 Q36848552-E3DCFF07-F581-4B58-8E34-35BD7C122D92 Q36871638-A50BFB69-3FA0-4836-A705-07F753F4F74C Q37151112-50446F06-EA5A-486A-B75B-09A524BC639E Q37174939-05CAF2D8-DFC8-4C92-B818-BC024C6169FE Q37191359-21BEAF2A-4F17-4547-8056-EDE2FA4B51E1 Q37277436-F838CD8E-893C-4869-8D61-CB038BB5CF96

P2860

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.

http://www.wikidata.org/entity/Q33401476

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

A retrospective study of neoad ...... ced pancreatic adenocarcinoma.

@ast

A retrospective study of neoad ...... ced pancreatic adenocarcinoma.

@en

type

label

A retrospective study of neoad ...... ced pancreatic adenocarcinoma.

@ast

A retrospective study of neoad ...... ced pancreatic adenocarcinoma.

@en

prefLabel

A retrospective study of neoad ...... ced pancreatic adenocarcinoma.

@ast

A retrospective study of neoad ...... ced pancreatic adenocarcinoma.

@en

P1433

Q33401476-F5FDBBFE-35EE-4931-968D-1AB5711E8BC7

P1476

Q33401476-78F0D546-5900-4A08-8129-C3252C8D6CF5

P2093

Q33401476-227AFCEE-38CF-413F-8751-34BEEDC861FB

Q33401476-2C182095-FD96-40DF-B96F-1562ED33542C

Q33401476-2EBD14DC-7F63-4E00-97EC-13C2378D9148

Q33401476-32360419-596F-4A38-808E-991B0A776273

Q33401476-4BC93204-92B0-4A1C-AE92-A0424A66A51B

Q33401476-65FBF62B-C348-4B76-BC7F-FCA85CA49E55

Q33401476-90E58533-2BD6-4D85-B0B0-A4C331ACC1DB

Q33401476-CAA52F2F-848F-4903-9B5F-3B1831949452

Q33401476-D71AC7EB-9BAE-4C76-9A6E-837CD21C8BD9

Q33401476-EEF1C23E-D635-40FD-A86B-790BB6120F61

P2860

Q33401476-04C83260-71D0-4461-890F-34EF3B07A9FD

Q33401476-2BC48361-BF1F-42D9-868B-D483DA939FC0

Q33401476-393303C1-3BC8-4C6D-A1E3-D41E6EBF1C00

Q33401476-3F26BEE7-5A10-4E45-B423-E489FBDAF1E8

Q33401476-CD73B17C-AFD9-4EEC-B611-2CA24B02B224

Q33401476-FFC1CE29-4188-4340-899F-6F0CE6181098

P2888

Q33401476-94627AD3-20A0-40CE-9BC0-B88005AA581D

P304

Q33401476-0A80C658-A9AE-4C1D-B31C-0554624BB294

P31

Q33401476-77F81FE6-0399-42C3-BE57-1EEFAE325B55

P356

Q33401476-47E281C5-B5F4-4332-A217-2A96DD142F5E

P407

Q33401476-AE708537-BEB8-44CE-AEEF-80DF3BAF07E1

P478

Q33401476-5EE9507F-9BEE-4AA0-A35E-1CE6A80E6FD1

P50

Q33401476-24338BA7-1C78-43AC-9C84-8F21EF065333

P577

Q33401476-73E3C793-8962-4116-817C-6129954649E3

P5875

Q33401476-DE5CB914-B524-4D59-A58F-A097145D62AC

P6179

Q33401476-5C55F7B3-F0B1-48A1-9BA9-4457AD4776EE

P698

Q33401476-D0DB717A-0FF6-47B7-B214-6D171A4D3464

P921

Q33401476-C790A067-ED15-42FC-B8DB-BF7EB5035471

P932

Q33401476-0ADA03E0-4578-414B-9E67-DAD58BECE719

P356

1471-2407-12-199

P1433

P1476

A retrospective study of neoad ...... ced pancreatic adenocarcinoma.

@en

P2093

Afonso Ribeiro

http://www.w3.org/2001/XMLSchema#string

Caio M Rocha-Lima

http://www.w3.org/2001/XMLSchema#string

Carolina Kawamura

http://www.w3.org/2001/XMLSchema#string

Govindarajan Narayanan

http://www.w3.org/2001/XMLSchema#string

Jaime R Merchan

http://www.w3.org/2001/XMLSchema#string

Jennifer Cudris Maldonado

http://www.w3.org/2001/XMLSchema#string

Jessica Macintyre

http://www.w3.org/2001/XMLSchema#string

Joe U Levi

http://www.w3.org/2001/XMLSchema#string

Lorraine Portelance

http://www.w3.org/2001/XMLSchema#string

Peter J Hosein

http://www.w3.org/2001/XMLSchema#string

P2860

Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.

Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement.

A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study.

Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

P2888

1471-2407-12-199

P304

199

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-12-199

http://www.w3.org/2001/XMLSchema#string

P407

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Arturo Loaiza-Bonilla

P577

2012-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225072295

http://www.w3.org/2001/XMLSchema#string

P6179

1046942754

http://www.w3.org/2001/XMLSchema#string

P698

22642850

http://www.w3.org/2001/XMLSchema#string

P921

P932

3404979

http://www.w3.org/2001/XMLSchema#string